Perrigo Company plc Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net
Perrigo Company plc (PRGO) reported Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net of $1.10 million for the 12-month period ending 2015-06-27, per its 10-K filed 2018-03-01.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet · last filed 2018-03-01
- Perrigo Company plc gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2015 was $1.10M.
| Period end | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 12 month |
|---|---|---|
| 2015-06-27 | $1.10M 10-K · filed 2018-03-01 | |
| 2014-12-02 | $1.10M 10-K · filed 2017-05-22 | |
| 2013-12-18 | $500.00K 10-K · filed 2017-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |